Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Center for Research and Application of Cellular Therapy, Kyoto University Hospital, Kyoto, Japan.
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Center for Research and Application of Cellular Therapy, Kyoto University Hospital, Kyoto, Japan.
Cytotherapy. 2023 Apr;25(4):407-414. doi: 10.1016/j.jcyt.2022.10.005. Epub 2022 Nov 2.
While donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) in the recipient before transplantation are associated with graft failure in cord-blood transplantation (CBT), effects of DSAs other than against HLA-A, -B or -DRB1 on transplantation outcomes remained poorly understood.
We retrospectively analyzed 567 single-unit CBT recipients to evaluate impact of DSAs against HLA-DP and -DQ on CBT outcomes.
Among 143 recipients (25.2%) who had anti-HLA antibodies, nine harbored DSAs against HLA-DP or -DQ. DSAs against HLA-DP or -DQ were associated with a significantly lower neutrophil engraftment rate (55.6% versus 91.8%, P = 0.032) and with a marginally lower platelet engraftment rate (46.7% versus 75.3%, P = 0.128) at day 100 after transplantation, compared with patients without anti-HLA antibodies. Time to neutrophil and platelet engraftment in patients with DSAs for HLA-DP or -DQ was significantly longer than that in patients without anti-HLA antibodies (median, 25 versus 21 days, P = 0.002 in neutrophil; median 61 versus 46 days, P = 0.014 in platelet). Cumulative incidence of bacterial infection at day 100 was significantly greater (88.9% versus 57.1%, P = 0.024), and re-transplant-free survival was marginally lower (55.6% versus 76.8%, P = 0.132) in patients with DSAs against HLA-DP or -DQ, compared with those without anti-HLA antibodies. These findings suggest that DSAs against HLA-DP or -DQ lead to unfavorable engraftment, which may increase risk of bacterial infection, and reduce survival soon after CBT.
Our results suggest the importance of evaluating DSAs against HLA-DP and -DQ in recipients before selecting CB units.
虽然移植前受者体内针对人白细胞抗原（HLA）的供体特异性抗体（DSA）与脐血移植（CBT）中的移植物衰竭有关，但除 HLA-A、-B 或 -DRB1 以外的 DSA 对移植结局的影响仍知之甚少。
我们回顾性分析了 567 例单份 CBT 受者，以评估针对 HLA-DP 和 -DQ 的 DSA 对 CBT 结局的影响。
在 143 例（25.2%）有抗 HLA 抗体的受者中，有 9 例携带针对 HLA-DP 或 -DQ 的 DSA。与无抗 HLA 抗体的受者相比，针对 HLA-DP 或 -DQ 的 DSA 与显著较低的中性粒细胞植入率（55.6%比 91.8%，P=0.032）和边缘较低的血小板植入率（46.7%比 75.3%，P=0.128）相关，在移植后 100 天。针对 HLA-DP 或 -DQ 的 DSA 患者的中性粒细胞和血小板植入时间明显长于无抗 HLA 抗体的患者（中位数，25 天比 21 天，P=0.002；中位数，61 天比 46 天，P=0.014）。第 100 天的细菌感染累积发生率显著较高（88.9%比 57.1%，P=0.024），针对 HLA-DP 或 -DQ 的 DSA 患者的无复发生存率略低（55.6%比 76.8%，P=0.132），与无抗 HLA 抗体的患者相比。这些发现表明，针对 HLA-DP 或 -DQ 的 DSA 导致植入不良，这可能增加细菌感染的风险，并在 CBT 后不久降低生存率。
我们的结果表明，在选择 CB 单位之前，评估受者针对 HLA-DP 和 -DQ 的 DSA 非常重要。
